Your session is about to expire
← Back to Search
BID Dosing for Meibomian Gland Dysfunction (Ersa Trial)
Ersa Trial Summary
This trialtests a new eye drop to help people with Demodex lid infestation, comparing its safety and effectiveness when used twice daily vs three times daily.
- Meibomian Gland Dysfunction
- Demodex Mite Infestation
- Blepharitis
Ersa Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Ersa Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is there any availability for enrolment in this experiment?
"Affirmative. Clinicaltrials.gov indicates that this research trial, which was first announced on August 3rd 2022, is presently recruiting volunteers. 40 participants are needed from four distinct locations."
Could you elucidate to what degree TID Dosing poses a risk for patients?
"We have assigned TID Dosing a score of 2, since there is some data indicating its safety but no clinical evidence backing up its efficacy."
What locations in Canada are conducting this medical research?
"This scientific research is being conducted at Silverstein Eye Center in Kansas City, Missouri, Medical Optometry America in New Freedom, Pennsylvania and Mitchell C. Shultz MD in Northridge, California as well as extra 4 sites."
How many participants are currently enrolled in this trial?
"Tarsus Pharmaceuticals, Inc. will be spearheading this research project and requires 40 eligible participants to commence the study at two different locations - Silverstein Eye Center of Kansas City, Missouri and Medical Optometry America in New Freedom, Pennsylvania."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger